Ipsen shares jump as 2026 guidance exceeds expectations

Shares of the French pharmaceutical giant Ipsen surged more than 6% on European markets Wednesday morning after the company significantly upgraded its 2026 financial guidance during a high-profile Capital Markets Day. The Paris-based firm raised its mid-term targets following a period of robust organic growth and a series of successful strategic acquisitions that have bolstered its oncology and rare disease pipelines. Investors responded enthusiastically to the news, pushing the stock to its highest level in several months as the company demonstrated a stronger-than-anticipated trajectory for its portfolio expansion. Under the leadership of CEO David Loew, Ipsen now projects an average annual revenue growth of at least 7% between 2023 and 2026, a notable increase from previous estimates. Furthermore, the company expects its core operating margin to reach approximately 32% by 2026. This optimistic outlook is fueled by the performance of its top-selling products, such as the cancer treatment Cabometyx, and the integration of newer assets like Bylvay, which targets rare liver diseases. The company’s strategy of refocusing on specialty medicines appears to be yielding higher returns than the broader market had priced in. Financial analysts noted that the revised guidance reflects a healthy balance between internal research and development and external business development. By successfully navigating patent cliffs for older products and securing regulatory approvals for new indications, Ipsen has managed to de-risk its future revenue streams. The upward revision not only underscores the company's operational efficiency but also reaffirms its position as a major player in the European biotech and pharmaceutical sector, potentially setting a new benchmark for its mid-cap peers in terms of growth expectations.